113 related articles for article (PubMed ID: 35189054)
21. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of Essential Thrombocythemia to Acute Myeloid Leukemia].
Lin P; Xie RT; Zhang YL; Zhang XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):411-417. PubMed ID: 32319371
[TBL] [Abstract][Full Text] [Related]
23. JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers.
Vicente C; Vázquez I; Marcotegui N; Conchillo A; Carranza C; Rivell G; Bandrés E; Cristobal I; Lahortiga I; Calasanz MJ; Odero MD
Leukemia; 2007 Nov; 21(11):2386-90. PubMed ID: 17581610
[No Abstract] [Full Text] [Related]
24. The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia.
Zhong Y; Chen B; Feng J; Cheng L; Li Y; Qian J; Ding J; Gao F; Xia G; Chen N; Lu Z
Leuk Lymphoma; 2010 Jun; 51(6):1115-20. PubMed ID: 20536350
[TBL] [Abstract][Full Text] [Related]
25. JAK2 V617F mutation is uncommon in patients with the 3q21q26 syndrome.
Lin P; Luthra R; Nussenzveig RH; Medeiros LJ
Hum Pathol; 2010 May; 41(5):758-62. PubMed ID: 20153505
[TBL] [Abstract][Full Text] [Related]
26. [Detection of JAK2V617F mutation and its clinical significance in 80 patients with M2 acute myelogenous leukemia].
Shen YM; Chao HY; Zhang R; Li WY; Feng YF; Zhu ZL; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):366-70. PubMed ID: 19799086
[TBL] [Abstract][Full Text] [Related]
27. JAK2 and Beyond: Mutational Study of JAK2V617 in Myeloproliferative Disorders and Haematological Malignancies in Kashmiri population.
Syeed N
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3611-3615. PubMed ID: 31870101
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and phenotypes of
Cordua S; Kjaer L; Skov V; Pallisgaard N; Hasselbalch HC; Ellervik C
Blood; 2019 Aug; 134(5):469-479. PubMed ID: 31217187
[TBL] [Abstract][Full Text] [Related]
29. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
[TBL] [Abstract][Full Text] [Related]
30. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
31. Targeted signal transduction therapies in myeloid malignancies.
Scott E; Hexner E; Perl A; Carroll M
Curr Oncol Rep; 2010 Nov; 12(6):358-65. PubMed ID: 20809224
[TBL] [Abstract][Full Text] [Related]
32. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
[TBL] [Abstract][Full Text] [Related]
33. V617F-independent upregulation of JAK2 gene expression in patients with inflammatory bowel disease.
Asadzadeh-Aghdaei H; Mashayekhi K; Koushki K; Azimzadeh P; Rostami-Nejad M; Amani D; Chaleshi V; Haftcheshmeh SM; Sahebkar A; Zali MR
J Cell Biochem; 2019 Sep; 120(9):15746-15755. PubMed ID: 31069840
[TBL] [Abstract][Full Text] [Related]
34. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?
Pasqualucci L; Li S; Meloni G; Schnittger S; Gattenlohner S; Liso A; Di Ianni M; Martelli MP; Pescarmona E; Foa R; Haferlach T; Skoda RC; Falini B
Leukemia; 2008 Jul; 22(7):1459-63. PubMed ID: 18200037
[No Abstract] [Full Text] [Related]
35. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
[TBL] [Abstract][Full Text] [Related]
36. Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia.
Wu QY; Ma MM; Zhang S; Liu Y; Cao J; Yan ZL; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
Int J Biol Macromol; 2019 Mar; 124():1123-1131. PubMed ID: 30521925
[TBL] [Abstract][Full Text] [Related]
37. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
38. FLT3 mutations in myeloproliferative neoplasms: the Beaumont experience.
Williams L; Kelley HH; Meng X; Prada A; Crisan D
Diagn Mol Pathol; 2013 Sep; 22(3):156-60. PubMed ID: 23846442
[TBL] [Abstract][Full Text] [Related]
39. A case-control study in NAT2 gene polymorphism studies in patients diagnosed with acute myeloid leukemia.
Farasani A
Acta Biochim Pol; 2023 Sep; 70(3):503-507. PubMed ID: 37715989
[TBL] [Abstract][Full Text] [Related]
40. Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Lewandowski K; Gniot M; Wojtaszewska M; Kanduła Z; Becht R; Paczkowska E; Mędraś E; Wasilewska E; Iwoła M
Int J Lab Hematol; 2018 Jun; 40(3):366-371. PubMed ID: 29508552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
